New radiation approach aims to spare healthy tissue in sinus cancer treatment

NCT ID NCT05943119

Recruiting now Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effects like damage to the nose, eyes, ears, and brain. About 52 adults with sinus tumors will be randomly assigned to either the new targeted radiation or standard full-sinus radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (dose-painting radiation)
What this could lead to: If successful, this approach could reduce severe side effects from radiation while still controlling sinus cancer.
What could go wrong: This is a small, early-phase trial (52 people). It may not show a clear benefit, and the targeted method might miss some cancer cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR OF THE SINUSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fistula neoplasm paranasal sinus cancer paranasal sinus carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

CHU CAEN
NOT_YET_RECRUITING

Caen, France
Centre Francois Baclesse
RECRUITING

Caen, France
Centre Oscar Lambret
NOT_YET_RECRUITING

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.